Topic Editors

Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37124 Verona, Italy
Department of Computer Science, University of Verona, Verona, Italy
Department of Neurosciences, Biomedicine and Movement Sciences, Anatomy and Histology Section, University of Verona, 37134 Verona, Italy

Nanomedical Research

Abstract submission deadline
closed (30 July 2023)
Manuscript submission deadline
closed (30 September 2023)
Viewed by
7969

Topic Information

Dear Colleagues,

Nanomedicine is a rapidly evolving research area with a strong interdisciplinary character, requiring the interaction of scientists from different disciplines, such as chemistry, engineering, physics, biology, biotechnology, medicine, and pharmacology. Nanoconstructs intended for biomedical purposes cover a wide variety of potential applications: systems for the targeted delivery of therapeutic compounds; agents for bioimaging; biosensors; biomarkers; robots at the molecular scale; components for membranes, coatings, films, or scaffolds; etc.

This Topic aims to collect articles dealing with any aspect of nanoscience and nanotechnology applied to biology and medicine, from the design, synthesis, and characterization of novel nanomaterials and nanoconstructs to the evaluation of their effects in applications within the biomedical field. Particular attention is devoted to the development of innovative methodological approaches and technological tools.

The Topic is open to basic and applied science as well as to preclinical studies; submissions of both original research and review articles from researchers, clinicians, and the industry are all welcome.

Prof. Manuela Malatesta
Prof. Dr. Federico Boschi
Dr. Flavia Carton
Topic Editors

Keywords

  • nanomaterials
  • nanoparticles
  • nanodiamonds
  • nanorobots
  • nanoscaffolds
  • nanosensors
  • nanotubes
  • nanodiagnostic device
  • quantum dots
  • nanomedicine
  • nanotoxicology
  • targeted drug delivery
  • biomedical imaging
  • microscopy

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Biomedicines
biomedicines
3.9 5.2 2013 15.3 Days CHF 2600
Current Issues in Molecular Biology
cimb
2.8 2.9 1999 16.8 Days CHF 2200
International Journal of Molecular Sciences
ijms
4.9 8.1 2000 18.1 Days CHF 2900
Nanomaterials
nanomaterials
4.4 8.5 2010 13.8 Days CHF 2900
Pharmaceutics
pharmaceutics
4.9 7.9 2009 14.9 Days CHF 2900

Preprints.org is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

  1. Immediately share your ideas ahead of publication and establish your research priority;
  2. Protect your idea from being stolen with this time-stamped preprint article;
  3. Enhance the exposure and impact of your research;
  4. Receive feedback from your peers in advance;
  5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (3 papers)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
19 pages, 4624 KiB  
Article
Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease
by Marina Beraza-Millor, Julen Rodríguez-Castejón, Jonatan Miranda, Ana del Pozo-Rodríguez, Alicia Rodríguez-Gascón and María Ángeles Solinís
Pharmaceutics 2023, 15(7), 1936; https://doi.org/10.3390/pharmaceutics15071936 - 12 Jul 2023
Cited by 5 | Viewed by 1798
Abstract
Substrate reduction therapy (SRT) has been proposed as a new gene therapy for Fabry disease (FD) to prevent the formation of globotriaosylceramide (Gb3). Nanomedicines containing different siRNA targeted to Gb3 synthase (Gb3S) were designed. Formulation factors, such as the composition, solid lipid nanoparticles [...] Read more.
Substrate reduction therapy (SRT) has been proposed as a new gene therapy for Fabry disease (FD) to prevent the formation of globotriaosylceramide (Gb3). Nanomedicines containing different siRNA targeted to Gb3 synthase (Gb3S) were designed. Formulation factors, such as the composition, solid lipid nanoparticles (SLNs) preparation method and the incorporation of different ligands, such as gold nanoparticles (GNs), protamine (P) and polysaccharides, were evaluated. The new siRNA–golden LNPs were efficiently internalized in an FD cell model (IMFE-1), with GNs detected in the cytoplasm and in the nucleus. Silencing efficacy (measured by RT-qPCR) depended on the final composition and method of preparation, with silencing rates up to 90% (expressed as the reduction in Gb3S-mRNA). GNs conferred a higher system efficacy and stability without compromising cell viability and hemocompatibility. Immunocytochemistry assays confirmed Gb3S silencing for at least 15 days with the most effective formulations. Overall, these results highlight the potential of the new siRNA–golden LNP system as a promising nanomedicine to address FD by specific SRT. Full article
(This article belongs to the Topic Nanomedical Research)
Show Figures

Graphical abstract

26 pages, 4983 KiB  
Article
Immunosuppressive Polymeric Nanoparticles Targeting Dendritic Cells Alleviate Lupus Disease in Fcgr2b-/- Mice by Mediating Antigen-Specific Immune Tolerance
by Phuriwat Khiewkamrop, Chamraj Kaewraemruaen, Chonnavee Manipuntee, Chalathan Saengruengrit, Numpon Insin, Asada Leelahavanichkul, Warerat Kaewduangduen, Opor Sonpoung, Kasirapat Ariya-anandech, Nattiya Hirankarn and Patcharee Ritprajak
Int. J. Mol. Sci. 2023, 24(9), 8313; https://doi.org/10.3390/ijms24098313 - 5 May 2023
Cited by 3 | Viewed by 2171
Abstract
Dendritic cells (DCs) are the most potent antigen-presenting cells that have multifaceted functions in the control of immune activation and tolerance. Hyperresponsiveness and altered tolerogenicity of DCs contribute to the development and pathogenesis of system lupus erythematosus (SLE); therefore, DC-targeted therapies aimed at [...] Read more.
Dendritic cells (DCs) are the most potent antigen-presenting cells that have multifaceted functions in the control of immune activation and tolerance. Hyperresponsiveness and altered tolerogenicity of DCs contribute to the development and pathogenesis of system lupus erythematosus (SLE); therefore, DC-targeted therapies aimed at inducing specific immune tolerance have become of great importance for the treatment of SLE. This study developed a new nanoparticle (NP) containing a biodegradable PDMAEMA-PLGA copolymer for target-oriented delivery to DCs in situ. PDMAEMA-PLGA NPs provided sustained drug release and exhibited immunosuppressive activity in FLT3L and GM-CSF-derived bone marrow in conventional DCs (BM-cDCs). PDMAEMA-PLGA NPs improved dexamethasone capability to convert wild-type and Fcgr2b-/- BM-cDCs from an immunogenic to tolerogenic state, and BM-cDCs treated with dexamethasone-incorporated PDMAEMA-PLGA NPs (Dex-NPs) efficiently mediated regulatory T cell (Treg) expansion in vitro. Dex-NP therapy potentially alleviated lupus disease in Fcgr2b-/- mice by mediating Foxp3+ Treg expansion in an antigen-specific manner. Our findings substantiate the superior efficacy of DC-targeted therapy using the PDMAEMA-PLGA NP delivery system and provide further support for clinical development as a potential therapy for SLE. Furthermore, PDMAEMA-PLGA NP may be a versatile platform for DC-targeted therapy to induce antigen-specific immune tolerance to unwanted immune responses that occur in autoimmune disease, allergy, and transplant rejection. Full article
(This article belongs to the Topic Nanomedical Research)
Show Figures

Figure 1

16 pages, 1728 KiB  
Review
HIV Latency and Nanomedicine Strategies for Anti-HIV Treatment and Eradication
by Mickensone Andre, Madhavan Nair and Andrea D. Raymond
Biomedicines 2023, 11(2), 617; https://doi.org/10.3390/biomedicines11020617 - 18 Feb 2023
Cited by 6 | Viewed by 2836
Abstract
Antiretrovirals (ARVs) reduce Human Immunodeficiency Virus (HIV) loads to undetectable levels in infected patients. However, HIV can persist throughout the body in cellular reservoirs partly due to the inability of some ARVs to cross anatomical barriers and the capacity of HIV-1 to establish [...] Read more.
Antiretrovirals (ARVs) reduce Human Immunodeficiency Virus (HIV) loads to undetectable levels in infected patients. However, HIV can persist throughout the body in cellular reservoirs partly due to the inability of some ARVs to cross anatomical barriers and the capacity of HIV-1 to establish latent infection in resting CD4+ T cells and monocytes/macrophages. A cure for HIV is not likely unless latency is addressed and delivery of ARVs to cellular reservoir sites is improved. Nanomedicine has been used in ARV formulations to improve delivery and efficacy. More specifically, researchers are exploring the benefit of using nanoparticles to improve ARVs and nanomedicine in HIV eradication strategies such as shock and kill, block and lock, and others. This review will focus on mechanisms of HIV-1 latency and nanomedicine-based approaches to treat HIV. Full article
(This article belongs to the Topic Nanomedical Research)
Show Figures

Figure 1

Back to TopTop